Esperite (voorheen Cryo Save) « Terug naar discussie overzicht

quote:

bik schreef op 14 augustus 2019 14:38:

Ach wat,Pharming heeft ooit ook op 0,04 gestaan.Dus waarom dit Gouden Aandeeltje niet op 1E.??? Geef me 1 goederede. Grrr.

quote:

bik schreef op 15 augustus 2019 10:58:

Ze benne anders wel lekker goedkoop geworden,gokje waard voor 0,06. Grrr.

quote:

bik schreef op 15 augustus 2019 17:07:

You must never try to catch a falling knife,mien Ritter. Grrrr.

quote:

DeZwarteRidder schreef op 15 augustus 2019 10:59:

[...]
Voor goedkoop moet je bij de Action zijn.

quote:

Jona Investments schreef op 27 augustus 2019 15:10:

what the fuck is happening now? UP 15%

quote:

Hofnar schreef op 27 augustus 2019 16:25:

[...]ESPERITE NV AND MYRISOPH CAPITAL CONCLUDE A STRATEGIC AGREEMENT ON CRYO-SAVE’S FAMILY STEM CELL BANKING BUSINESS
Amsterdam, The Netherlands – 27 August 2019
Esperite N.V. (Euronext: ESP) and Myrisoph Capital Inc (Myrisoph) are pleased to announce that they have concluded a strategic agreement related to Cryo-Save’s stem cell cryopreservation business. Myrisoph becomes the exclusive global licensee of the CryoSave brand for a minimum period of ten (10) years. Along with Cryo-Save’s long-established quality history and service, the transaction leverages Myrisoph Capital’s experience and success in turning around Medical, Laboratory and Biotech companies – including Cryo-Save Arabia, the first Stem Cell Bank in the Middle-East and North Africa region, and currently one of the more profitable cord blood banks worldwide.
Cryo-Save is one of the largest and longest operating stem cell banks in Europe, having stored more than 330.000 umbilical cord blood samples and tissues over the past 20 years.
As Part of the transaction, Myrisoph Capital takes over the responsibility for the marketing and sales of the brand as well as the storage of all samples stored to date, to continue serving the clients with the utmost care.
Myrisoph will also revitalize the brand with the explicit goal of ranking CryoSave to the top 5 Family Stem Cell Banks worldwide.
“We are excited about the acquisition of Cryo-Save’s global business. For more than 14 years we own and manage a profitable and very successful Family Stem Cell Bank. We are confident that our management team will turn Cryo-Save into a global leader by implementing our best practices. to. We have the financial resources to invest substantially in the growth of the business for the benefit of all our current and future clients. We will conduct laboratory and storage operations in Switzerland under the highest Swiss and global standards. Our priority will be to ensure that existing and future clients will be fully satisfied. We will immediately implement the necessary changes to provide world class and reliable service that the Cryo- Save brand has come to represent” – commented Hassan Alhassani, the President of Myrisoph Capital Inc.
Esperite will convene an extraordinary shareholders' meeting within the next couple of weeks.